Agenovir Lands $10,600,000 Series A Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a467dbdc-96dc-4941-ba22-7efcaa4798bd
Date
5/18/2016
Company Name
Agenovir
Mailing Address
329 Oyster Point Blvd. 3rd Floor South San Francisco, CA 94080 USA
Company Description
Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with or caused by latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited or non-existent.
Website
http://www.agenovir.com
Transaction Type
Venture Equity
Transaction Amount
$10,600,000
Transaction Round
Series A
Proceeds Purposes
With this financing led by top tier venture, corporate and individual investors, we expect to build an exceptional leadership team and accelerate our research and development programs to treat diseases associated or caused by latent or persistent viral reservoirs.
M&A Terms
Venture Investor
Data Collective
Venture Investor
Celgene
Venture Investor
Lightspeed Venture Partners
Venture Investor
Undisclosed